Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study

INTRODUCTION: Nocturnal hypertension is clinically important for patients with type 2 diabetes (T2D), considering its strong correlation with cardiovascular events. We aim to test the hypothesis that the sodium-glucose cotransporter 2 inhibitor, luseogliflozin, ameliorates nocturnal hypertension mor...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMJ Open
Autori principali: Kameda, Reina, Nomoto, Hiroshi, Cho, Kyu Yong, Kawata, Shinichiro, Omori, Kazuno, Takeuchi, Jun, Nagai, So, Kurihara, Yoshio, Aoki, Shin, Nakamura, Akinobu, Atsumi, Tatsuya, Miyoshi, Hideaki
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2020
Soggetti:
Diabetes and Endocrinology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7044823/
https://ncbi.nlm.nih.gov/pubmed/32034028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-034883
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi